# EDGAR Filing Document

**Accession Number:** 0001724521
**File Stem:** 0001209191-23-017833
**Filing Date:** 2023-3
**Character Count:** 9577
**Document Hash:** 3b1b9510d10a955bc2ed9b4002278709
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-017833.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0001209191-23-017833

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230309

**FILED AS OF DATE**: 20230310

**DATE AS OF CHANGE**: 20230310

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Azoy Alexander
- **CENTRAL INDEX KEY:** 0001771961

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38419
- **FILM NUMBER:** 23724399

**MAIL ADDRESS:**
- **STREET 1:** 30699 RUSSELL RANCH ROAD, SUITE 140
- **CITY:** WESTLAKE VILLAGE
- **STATE:** CA
- **ZIP:** 91362
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Arcus Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001724521
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 473898435
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 3928 POINT EDEN WAY
- **CITY:** HAYWARD
- **STATE:** CA
- **ZIP:** 94545
- **BUSINESS PHONE:** (510) 694-6200

**MAIL ADDRESS:**
- **STREET 1:** 3928 POINT EDEN WAY
- **CITY:** HAYWARD
- **STATE:** CA
- **ZIP:** 94545

## Ex-24

```

LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS

The undersigned, as a Section 16 reporting person of Arcus Biosciences, Inc., a
Delaware corporation (the "Company"), hereby constitutes and appoints each of
Terry Rosen, Ph.D., Juan C. Jaen, Ph.D., Carolyn Tang, Nicholas Griffin, Jason
Barker, Jennifer Yip, Kenneth Guernsey and Brett White signing individually, the
undersigned's true and lawful attorney-in-fact to:

1. complete and execute Form ID, "Update Passphrase Confirmation" form and Forms
3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact
shall in his or her discretion determined to be required or advisable pursuant
to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules
and regulations promulgated thereunder, or any successor laws and regulations,
as a consequence of the undersigned's ownership, acquisition or disposition of
securities of the Company; and

2. do all acts necessary in order to file such forms with the Securities and
Exchange Commission, any securities exchange or national association, the
Company and such other person or agency as the attorney-in-fact shall deem
appropriate.
The undersigned hereby grants to the attorneys-in-fact full power and authority
to do and perform any and every act and thing whatsoever requisite, necessary or
proper to be done in the exercise of any of the rights and powers herein granted
and hereby ratifies and confirms all that said attorneys-in-fact and agents
shall do or cause to be done by virtue of this Power of Attorney. The
undersigned acknowledges that the foregoing attorneys-in-fact, in serving in
such capacity at the request of the undersigned, are not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with the
Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of March 9, 2023.

By: /s/ Alexander Azoy
Name: Alexander Azoy

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Azoy Alexander<br><sub>(Last) (First) (Middle)</sub><br>C/O ARCUS BIOSCIENCES, INC.<br>3928 POINT EDEN WAY<br><sub>(Street)</sub><br>HAYWARD, CA 94545<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Arcus Biosciences, Inc. [ RCUS ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-03-09 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Accounting Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 690 | D |  |
| Common Stock | 216<sup>(1)</sup> | D |  |
| Common Stock | 3187<sup>(2)</sup> | D |  |
| Common Stock | 2375<sup>(3)</sup> | D |  |
| Common Stock | 5128<sup>(4)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | <sup>(5)</sup> | 2030-11-07 | Common Stock | 87500 | $21.53 | D |  |
| Stock Option (Right to Buy) | <sup>(6)</sup> | 2031-03-07 | Common Stock | 867 | $31.49 | D |  |
| Stock Option (Right to Buy) | <sup>(7)</sup> | 2032-03-08 | Common Stock | 8500 | $33.03 | D |  |
| Stock Option (Right to Buy) | <sup>(8)</sup> | 2033-01-22 | Common Stock | 9500 | $22.02 | D |  |

---

### Footnotes:

(1) Represents restricted stock units that were granted on March 8, 2021. The remaining RSUs will vest in two equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Issuer through such vesting date.

(2) Represents restricted stock units that were granted on March 8, 2022. The remaining RSUs will vest in three equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Issuer through such vesting date.

(3) Represents restricted stock units that were granted on December 15, 2022. The remaining RSUs will vest in two equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Issuer through such vesting date.

(4) Represents restricted stock units that were granted on January 23, 2023. The remaining RSUs will vest in four equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Issuer through such vesting date.

(5) This option was granted on November 9, 2020, with the total number of shares of common stock subject to this option vesting in 48 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through such vesting date. As of the date of this filing, 45,833 of the shares of common stock subject to this option were exercisable.

(6) This option was granted on March 8, 2021, with the total number of shares of common stock subject to this option vesting in 48 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through such vesting date. As of the date of this filing, 470 of the shares of common stock subject to this option were exercisable.

(7) This option was granted on March 8, 2022 with the total number of shares of common stock subject to this option vesting in 48 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through such vesting date. As of the date of this filing, 2,479 of the shares of common stock subject to this option were exercisable.

(8) This option was granted on January 23, 2023, with the total number of shares of common stock subject to this option vesting in 48 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through such vesting date. As of the date of this filing, 396 of the shares of common stock subject to this option were exercisable.

**Signature:** /s/ Carolyn Tang, Attorney-in-Fact  
**Date:** 2023-03-10

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**